JP2014513088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513088A5 JP2014513088A5 JP2014506794A JP2014506794A JP2014513088A5 JP 2014513088 A5 JP2014513088 A5 JP 2014513088A5 JP 2014506794 A JP2014506794 A JP 2014506794A JP 2014506794 A JP2014506794 A JP 2014506794A JP 2014513088 A5 JP2014513088 A5 JP 2014513088A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- period
- dose
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 210000003719 b-lymphocyte Anatomy 0.000 claims 11
- 230000002411 adverse Effects 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000027765 speech disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479961P | 2011-04-28 | 2011-04-28 | |
| US61/479,961 | 2011-04-28 | ||
| PCT/EP2012/001857 WO2012146394A1 (en) | 2011-04-28 | 2012-04-30 | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017194928A Division JP6539709B2 (ja) | 2011-04-28 | 2017-10-05 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513088A JP2014513088A (ja) | 2014-05-29 |
| JP2014513088A5 true JP2014513088A5 (https=) | 2015-06-25 |
| JP6276175B2 JP6276175B2 (ja) | 2018-02-07 |
Family
ID=46178514
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506794A Active JP6276175B2 (ja) | 2011-04-28 | 2012-04-30 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
| JP2017194928A Active JP6539709B2 (ja) | 2011-04-28 | 2017-10-05 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017194928A Active JP6539709B2 (ja) | 2011-04-28 | 2017-10-05 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10191034B2 (https=) |
| EP (2) | EP3753572A1 (https=) |
| JP (2) | JP6276175B2 (https=) |
| KR (2) | KR102345943B1 (https=) |
| CN (2) | CN103648529A (https=) |
| AU (2) | AU2012247762B2 (https=) |
| CA (1) | CA2832360C (https=) |
| ES (1) | ES2806142T3 (https=) |
| MX (1) | MX354371B (https=) |
| WO (1) | WO2012146394A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54655B2 (sr) * | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
| KR102345943B1 (ko) * | 2011-04-28 | 2021-12-31 | 암젠 리서치 (뮌헨) 게엠베하 | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| JP6499079B2 (ja) * | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| KR102211837B1 (ko) * | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| SI3149480T1 (sl) | 2014-05-30 | 2019-05-31 | Amgen Research (Munich) Gmbh | Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| EP3322735A4 (en) | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
| EP3747472B1 (en) | 2015-09-15 | 2024-04-03 | Acerta Pharma B.V. | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| US11827688B2 (en) * | 2016-06-02 | 2023-11-28 | Immunocore Limited | Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| AU2019355971B2 (en) | 2018-10-03 | 2025-05-08 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| TW202028244A (zh) * | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | 用於確定突觸形成之方法及系統 |
| CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| WO2020221792A1 (en) * | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| US20230093169A1 (en) * | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CA3199095A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| IL302412A (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| KR20250128342A (ko) * | 2022-12-21 | 2025-08-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 입양 면역요법을 위한 향상된 기능을 갖는 cd3 및 itcr을 발현하는 조작된 자연살해세포 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US7112324B1 (en) * | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| HRP20150175T1 (en) | 2005-12-16 | 2015-03-27 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| RU2769948C2 (ru) * | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| KR101695327B1 (ko) * | 2008-11-07 | 2017-01-11 | 암젠 리서치 (뮌헨) 게엠베하 | 급성 림프구성 백혈병의 치료방법 |
| RS54655B2 (sr) * | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
| EA026075B1 (ru) * | 2010-11-10 | 2017-02-28 | Эмджен Рисерч (Мьюник) Гмбх | Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами |
| KR102345943B1 (ko) * | 2011-04-28 | 2021-12-31 | 암젠 리서치 (뮌헨) 게엠베하 | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
-
2012
- 2012-04-30 KR KR1020207023808A patent/KR102345943B1/ko active Active
- 2012-04-30 WO PCT/EP2012/001857 patent/WO2012146394A1/en not_active Ceased
- 2012-04-30 JP JP2014506794A patent/JP6276175B2/ja active Active
- 2012-04-30 CN CN201280020887.XA patent/CN103648529A/zh active Pending
- 2012-04-30 EP EP20178760.3A patent/EP3753572A1/en active Pending
- 2012-04-30 US US14/113,755 patent/US10191034B2/en active Active
- 2012-04-30 KR KR1020137031150A patent/KR102147533B1/ko active Active
- 2012-04-30 EP EP12724289.9A patent/EP2701741B1/en active Active
- 2012-04-30 ES ES12724289T patent/ES2806142T3/es active Active
- 2012-04-30 MX MX2013012448A patent/MX354371B/es active IP Right Grant
- 2012-04-30 CN CN201710597419.3A patent/CN107303387A/zh active Pending
- 2012-04-30 CA CA2832360A patent/CA2832360C/en active Active
- 2012-04-30 AU AU2012247762A patent/AU2012247762B2/en active Active
-
2017
- 2017-08-21 AU AU2017218919A patent/AU2017218919A1/en not_active Abandoned
- 2017-10-05 JP JP2017194928A patent/JP6539709B2/ja active Active
-
2018
- 2018-12-12 US US16/217,366 patent/US11579142B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513088A5 (https=) | ||
| Decker et al. | The psychobiological links between chronic stress‐related diseases, periodontal/peri‐implant diseases, and wound healing | |
| Duhen et al. | IL-1β promotes the differentiation of polyfunctional human CCR6+ CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes | |
| MX354371B (es) | Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales. | |
| Zhao et al. | The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus | |
| Yli-Karjanmaa et al. | Topical administration of a soluble TNF inhibitor reduces infarct volume after focal cerebral ischemia in mice | |
| JP2014530226A5 (https=) | ||
| Aryankalayil et al. | Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells | |
| Takeuchi et al. | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) | |
| Selvaraj et al. | Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis | |
| MX2012004880A (es) | Pauta posologica para adminitrar un anticuerpo biespecifico cd19xcd3. | |
| Ortolan et al. | IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans | |
| JP2018500276A5 (https=) | ||
| EP3572095A1 (en) | Pharmaceutical composition used for treatment of htlv-1-associated myelopathy | |
| JP2016516985A5 (https=) | ||
| Fox et al. | Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients | |
| Park et al. | PD-1 deficiency protects experimental colitis via alteration of gut microbiota | |
| WO2017185085A1 (en) | Biomarkers for monitoring immune transformation | |
| JP2022507609A5 (https=) | ||
| Han et al. | Epigallocatechin gallate attenuates overload‑induced cardiac ECM remodeling via restoring T cell homeostasis | |
| US10226470B2 (en) | DGAT1 inhibition for treatment of demyelinating inflammatory disease | |
| FI3298042T3 (fi) | B-solujen vähentyminen diagnostisena merkkinä | |
| Takeuchi et al. | OP0149 A phase 2B study of an oral JAK inhibitor ASP015K monotherapy in Japanese patients with moderate to severe rheumatoid arthritis | |
| De Pablo et al. | AB0279 Incidence of diabetes and effect of etanercept and adalimumab on hba1c over 1 year: data from a randomised trial in patients with rheumatoid arthritis | |
| Hümmert et al. | Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab |